Technology Bundle ID
TAB-3555

Mutant IDH1 Inhibitors for Anticancer Therapy

Applications
Linked ID
E-189-2016-0
Lead Inventors
Matthew Boxer (NCATS)
Co-Inventors
Ajit Jadhav (NCATS)
Andrew McIver (University of North Carolina Chapel Hill)
Anton Simeonov (NCATS)
Jason Rohde (NCATS)
Kyle Brimacombe (NCATS)
Li Liu (NCATS)
Matthew Hall (NCATS)
Min Shen (NCATS)
Mindy Davis (NCATS)
Natalia Martinez (NCATS)
Rajan Pragani (NCATS)
Surendra Karavadhi (NCATS)
Wei Zhao (NCATS)
Xiaodong Wang (University of North Carolina Chapel Hill)
Yuhong Fang (NCATS)
ICs
This technology includes mutant isocitrate dehydrogenase (IDH1) inhibitors to be utilized as anticancer therapy. These potent inhibitors are aimed at lowering levels of the oncometabolite–2-hydroxyglutarate.
Commercial Applications
Anticancer agent that targets IDH1 mutations.

Request More Info

Licensing Contact: